This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D86.0 (Sarcoidosis of lung) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Pulmonary sarcoidosis, pulmonary granulomatosis, Sarcoidosis of lung, Boeck disease (lung) |
| C. Adult onset | Very likely to first manifest in adulthood — typically first manifests in adults aged 25–45, and in Korea the proportion with onset in the 50s–60s is increasing; childhood onset is rare. No sex difference, but a slightly higher morbidity rate in women has been reported. |
| 1. History | 1877 Jonathan Hutchinson reports skin and lymph node lesions → 1899 Caesar Boeck names it "benign miliary lupus" → 1934 Jörgen Schaumann reclassifies it as a systemic granulomatous disease → 1958 Scadding proposes a radiographic staging system → since the 2000s, large-scale epidemiologic studies published in Korea. |
| 2. Causes | Genetic predisposition (HLA-DRB1, etc.) + exposure to environmental antigens (Mycobacterium, Propionibacterium acnes, organic dust, metal dust) → non-caseating granuloma formation. Increased risk associated with occupation (firefighters, farmers, healthcare workers). |
| 3. Genetics | Polygenic inheritance (complex inheritance). HLA-DRB1 alleles (DRB1*0301, *1101) are the major susceptibility factors. Associations with ANXA11 and BTNL2 variants have been reported. Concordance in monozygotic twins ~40%. Not a single-gene disease. |
| 4. General epidemiology | Worldwide prevalence 10–20/100,000. Prevalence in Korea 9.37/100,000, incidence 0.85/100,000 (National Health Insurance data). Lung involvement accounts for 93.5% of all patients. Incidence is trending upward in women and in those in their 50s–60s. |
| 5. Pathophysiology | Inhalation of antigens (microbial/organic) → antigen presentation by alveolar macrophages and dendritic cells → CD4+ Th1 cell activation → secretion of TNF-α, IL-2, and IFN-γ → epithelioid granuloma formation. Granuloma fibrosis causes decline in lung function. |
| 6. Symptoms | Asymptomatic (incidental finding) or slowly progressive dry cough, dyspnea, chest pain, fatigue, fever, weight loss. Löfgren syndrome (erythema nodosum + arthritis + bilateral hilar lymphadenopathy) — acute, good prognosis. |
| 7. Signs | Chest X-ray: bilateral hilar lymphadenopathy (Scadding stage 1) · pulmonary infiltrates (stage 2) · pulmonary infiltrates alone (stage 3) · pulmonary fibrosis (stage 4). HRCT: interlobular thickening, peribronchovascular nodules, small confluent nodules. Pulmonary function: restrictive ventilatory defect, decreased DLco. |
| 8. Screening | Chest X-ray (first-line screening). In adults with persistent cough, dyspnea, or fatigue, HRCT and pulmonary function tests if the chest X-ray is abnormal. Serum ACE (low sensitivity, but useful as a reference for disease activity). Measurement of calcium and urinary calcium. Ophthalmologic examination (to exclude uveitis). |
| 9. Diagnosis | Bronchoscopic biopsy (TBLB/EBUS-TBNA): confirm non-caseating epithelioid granuloma. Bronchoalveolar lavage (BAL): CD4/CD8 ratio >3.5 is supportive. Diagnosis can be made without biopsy based on typical HRCT findings plus clinical context. Exclusion of tuberculosis is essential. |
| 10. Treatment | First line: oral corticosteroids (prednisolone 0.5 mg/kg/day up to a maximum of 40 mg). Second line: methotrexate, azathioprine, hydroxychloroquine. Third line: infliximab, adalimumab (TNF-α inhibition). Asymptomatic stage 1 and 2: observation. Start treatment when symptomatic or progressive. |
| 11. Prognosis | Spontaneous remission rate: stage 1 ~80%, stage 2 ~50–60%, stage 3 ~30%, stage 4 ~10%. Stage 4 accounts for 2% of Korean patients, lower than in the West. Overall mortality 9.25/1000 patients. Pulmonary hypertension and chronic respiratory failure are the main causes of death. |
| 12. Prevention | No specific preventive measures. Minimize occupational exposure to dust and organic antigens. Smoking cessation (to prevent worsening of lung damage). Detect progression early with regular pulmonary function tests. Follow up with chest X-ray and pulmonary function tests once a year. |
| 13. References | Valeyre D et al. Sarcoidosis. Lancet. 2014 … and 9 other papers |
The history of sarcoidosis begins with the development of dermatology in the late 19th century. In 1877, the British physician Jonathan Hutchinson first described a patient with purple nodular skin lesions on the hands and feet together with peripheral lymph node enlargement. He regarded these lesions as a skin disorder alone, but they were later confirmed to be the skin lesions of sarcoidosis (lupus pernio). Around the same time, Ernest Besnier of France independently reported similar skin lesions.
The name sarcoidosis was given in 1899 by the Norwegian dermatologist Caesar Boeck. He described small nodular granulomatous skin lesions under the name "benign miliary lupus," and the name sarcoidosis derives from the Greek "sarcoid (flesh-like)." Between the 1910s and 1930s, Jörgen Schaumann of Sweden argued that it is a systemic granulomatous disease involving not only the skin but also the lungs, lymph nodes, spleen, and other organs, and proposed the name "Schaumann's disease." Schaumann also emphasized that sarcoidosis is distinct from tuberculosis.
The importance of lung involvement came to the fore with the development of chest radiography. In 1958, the British chest physician John Scadding proposed a system, based on chest X-ray findings, dividing the radiologic staging of sarcoidosis into stage 0 (normal), stage 1 (bilateral hilar lymphadenopathy), stage 2 (hilar lymphadenopathy + pulmonary infiltrates), stage 3 (pulmonary infiltrates alone), and stage 4 (pulmonary fibrosis); this system is still widely used in clinical practice today (PMID: 13526905). In the 1960s–70s, bronchoalveolar lavage (BAL) and bronchoscopic biopsy techniques were introduced, greatly improving the accuracy of histologic diagnosis.
In Korea, case reports of sarcoidosis began to increase after the 1990s, and in the 2000s large-scale epidemiologic studies using National Health Insurance big data were published. In 2006, sarcoidosis was included in the Korean registration system for rare and intractable diseases, making it eligible for Special Copayment Reduction (V111). Nationwide Korean epidemiologic studies published in 2018–2021 confirmed that the clinical characteristics of sarcoidosis in Korea differ in part from those in the West (a lower proportion of stage 4 and a relatively older age at onset). More recently, the introduction of EBUS (endobronchial ultrasound) has made less invasive diagnostic methods commonplace, and biologic therapy, including TNF-α inhibitors, has become established as a treatment option for refractory sarcoidosis.
The exact cause of sarcoidosis has not yet been fully elucidated, but according to current understanding, an abnormal immune response to specific environmental antigens in genetically susceptible individuals leads to granuloma formation. It is a multifactorial disease in which multiple environmental and genetic factors are involved in combination rather than a single cause. This explains why sarcoidosis develops in only some of the people exposed to the same environment.
Among environmental factors, the most extensively studied are microbial antigens. Several studies have repeatedly reported that Mycobacterium tuberculosis antigens, particularly mycobacterial catalase-peroxidase (KatG), are detected in sarcoidosis granuloma tissue. In addition, Cutibacterium acnes (formerly Propionibacterium acnes) has been repeatedly detected in sarcoidosis tissue in Asian studies, including those from Japan, and is drawing attention as a candidate etiologic antigen. However, there is still debate over whether these microorganisms are the direct cause or have secondarily colonized already-formed granulomas.
Occupational and environmental exposures are also being studied as important causal factors. Epidemiologic studies show a higher incidence of sarcoidosis in firefighters, soldiers in conflict zones (particularly the New York firefighter cohort after 9/11), agricultural workers, metal industry workers, and healthcare workers. There is evidence that chronic exposure to organic dust (organic dust, mold spores), inorganic substances (silica, beryllium), and metals (aluminum, zirconium) can induce granuloma formation. Some studies have reported a paradoxical association in which smoking lowers the incidence of sarcoidosis, but in patients who have already developed the disease, smoking worsens lung damage.
The lung is the organ most commonly involved in sarcoidosis, with lung or hilar lymph node findings present in more than 90% of all patients. This is because the lung is the organ most directly exposed to environmental antigens, which supports the hypothesis that inhaled antigens are first recognized by alveolar macrophages and dendritic cells, initiating the immune response. Lung parenchymal involvement appears as the formation of non-caseating granulomas distributed in the bronchovascular, interlobular septal, and subpleural regions.
Sarcoidosis is not a single-gene disease but a complex genetic disease; genetic predisposition contributes to onset but does not by itself determine disease. Familial aggregation has been reported, and the risk of disease in first-degree relatives of sarcoidosis patients is 3–5 times higher than in the general population. The concordance rate in monozygotic twins is about 40%, showing that both genetic and environmental factors play important roles.
The risk gene most consistently reported in genetic association studies is the HLA (human leukocyte antigen) gene complex. In particular, HLA-DRB1 alleles are known as the strongest genetic risk factor; HLA-DRB1*0301 is associated with Löfgren syndrome and a good prognosis, whereas DRB1*1501 is associated with chronic progressive sarcoidosis. Specific amino acid sequences of HLA-DRB1 are interpreted as modulating the interaction between the presented antigenic peptide and the T-cell receptor, thereby determining the direction of the granuloma-forming response. HLA associations differ somewhat by ethnicity.
Among non-HLA risk genes, ANXA11 (annexin A11) is the most repeatedly identified variant. The ANXA11 R230C variant (rs1049550) has been reported to be independently associated with increased sarcoidosis risk in multiple ethnic groups. ANXA11 is a protein involved in cell division, apoptosis, and RNA splicing, and it has been proposed that this variant may affect immune cell function. Variants in the BTNL2 (butyrophilin-like 2) gene have also been reported to be associated with sarcoidosis, and this gene is involved in regulating T-cell activation. Other genes such as RAB23, OS9, and NOTCH4 have been suggested to be associated in some studies, but reproducibility is low.
Genome-wide association studies (GWAS) have found several small-effect risk variants across the genome, but the heritability explained by known common genetic variants is only about 33% of the total, of which 27% is explained by HLA-associated variants. This suggests that rare variants not yet discovered, gene-environment interactions, and epigenetic changes contribute to the remaining heritability. Currently, genetic testing for sarcoidosis is not recognized as a standardized test for diagnostic purposes and is used for research purposes only.
Sarcoidosis occurs worldwide, but prevalence and incidence differ considerably by region and ethnicity. Prevalence is high in Northern Europe (Sweden, Denmark) and among African Americans (about 64/100,000 and 40/100,000, respectively) and relatively low in East Asia, including Japan and Korea. The worldwide average prevalence is about 10–20/100,000.
In Korea, a nationwide study using National Health Insurance big data (published in Respiratory Research in 2018) reported a prevalence of 9.37/100,000 and an annual incidence of 0.85/100,000. A Korean patient cohort study published in Scientific Reports in 2021 showed a mean age at diagnosis of about 50 years, which is higher than in the West (peak in the 30s–40s), and in Korea there is a trend toward an increasing proportion of cases in the 50s–60s. The sex distribution is reported as a slightly higher proportion in women, and the incidence in Asian women, such as those in Japan and Korea, is relatively high.
In the distribution of organ involvement, the lung is the most commonly involved organ at 93.5%, followed by skin (24.3%), eyes (19.9%), and extrapulmonary lymph nodes (15.3%). By chest radiographic stage, in Korean patients stage 2 was most common (56.7%), followed by stage 1 (36.8%), stage 3 (3.8%), and stage 4 (2.6%). Compared with Western patients, in whom stage 4 reaches 5–15%, the proportion with advanced fibrosis is markedly lower in Korean patients, suggesting that the prognosis in Korea may be relatively favorable. The frequency of sarcoidosis-related metabolic diseases (diabetes, hypertension) occurring as complications has also been reported in domestic studies.
Sarcoidosis is classified as a rare disease and is included among the diseases eligible for Special Copayment Reduction V111 in Korea, with the copayment rate reduced to 10% for 5 years after registration. In an analysis of Korean National Health Insurance data from 2003–2015, the all-cause mortality of all sarcoidosis patients was relatively low at 9.25/1000, and pulmonary hypertension, cardiac involvement, and central nervous system involvement were factors associated with mortality.
The pathophysiology of pulmonary sarcoidosis is summarized as antigen-induced, T-cell-mediated granuloma formation. When a genetically susceptible individual inhales an external antigen such as Mycobacterium tuberculosis-derived protein, Cutibacterium acnes antigen, or an inorganic substance (such as silica), resident alveolar macrophages and dendritic cells (DC) phagocytose the antigen and present it, bound to MHC II molecules, to CD4+ T helper cells. Normally the immune response subsides after the antigen is cleared, but in sarcoidosis, antigen clearance is incomplete or immune regulation is abnormal, so the T-cell response persists.
Activated CD4+ T cells differentiate mainly into a Th1 phenotype and secrete IL-2, IFN-γ, TNF-α, and others. These cytokines further activate macrophages, causing them to differentiate into epithelioid cells and form multinucleated giant cells (Langhans type). Activated macrophages and epithelioid cells, together with surrounding lymphocytes and fibroblasts, become organized to form non-caseating, non-necrotizing granulomas. Unlike tuberculous granulomas, the absence of central necrosis is characteristic of sarcoidosis granulomas.
In the lung parenchyma, granulomas tend to be distributed in the bronchovascular bundle, interlobular septa, and subpleural region, which appears on HRCT as a characteristic centrilobular or perilymphatic nodular distribution. When many granulomas form, gas exchange impairment results along with lung parenchymal inflammation. Recovery is possible if granulomas resolve spontaneously or respond to treatment, but with repeated injury or persistent inflammation, TGF-β-mediated fibroblast activation leads to progression of irreversible pulmonary fibrosis, advancing to Scadding stage 4. At this stage it can lead to reduced lung volume, pulmonary hypertension, and right ventricular hypertrophy (cor pulmonale).
In addition, hypercalcemia can occur in sarcoidosis. When activated macrophages within granulomas express 1-α-hydroxylase and excessively convert 25-hydroxyvitamin D into the active form 1,25-dihydroxyvitamin D (calcitriol), intestinal calcium absorption increases, resulting in hypercalcemia and hypercalciuria. This can cause kidney stones and renal failure, and the presence of hypercalcemia is used as an indirect indicator suggesting sarcoidosis activity.
The clinical symptoms of pulmonary sarcoidosis are highly varied, and a substantial number of patients (particularly stage 1) are asymptomatic and discovered incidentally on chest X-ray. When symptoms are present, slowly progressive dry cough is the most common respiratory symptom, followed by dyspnea (exertional or at rest), chest discomfort or chest pain, generalized fatigue, fever, night sweats, and weight loss. Symptoms appear gradually over weeks to months, and sudden onset is rare.
A notable acute presentation is Löfgren syndrome. It is characterized by the triad of bilateral hilar lymphadenopathy (radiographic stage 1), erythema nodosum, and polyarthralgia or arthritis, and occurs mainly in young women. Löfgren syndrome occurs in about 10–15% of all sarcoidosis, has a high spontaneous remission rate (80–90%), and has a very good prognosis. Fever and systemic symptoms often accompany it, so it can be mistaken for an infectious or rheumatic disease.
Extrapulmonary symptoms also provide important clues for diagnosis. These may include ocular symptoms (uveitis, conjunctival nodules, corneal deposits), skin lesions (lupus pernio, erythema nodosum, sarcoid granulomatous skin lesions), neurologic symptoms (facial palsy, headache, cranial nerve palsy), cardiac symptoms (arrhythmia, conduction disturbance, heart failure), and hepatosplenomegaly. In many sarcoidosis patients, fatigue is the symptom that most impairs quality of life, and it does not necessarily correlate with radiologic findings or lung function. This fatigue occurs in combination with sleep disturbance, depression, and exercise intolerance and requires active management.
The severity of symptoms and the degree of lung function impairment do not always correspond to the radiologic stage. Some stage 4 patients may have relatively mild symptoms, whereas some stage 2–3 patients show severe dyspnea and impaired lung function. Therefore, disease activity and severity should be assessed by integrating clinical symptoms, radiologic findings, and pulmonary function tests.
On physical examination, many patients with pulmonary sarcoidosis have no or only mild abnormal findings. On auscultation, breath sounds may be normal or fine crackles may be heard on inspiration. When pulmonary fibrosis has progressed, crackles become distinct, and when pulmonary hypertension is present, an accentuated second heart sound and a tricuspid regurgitation murmur may be heard. Hepatosplenomegaly, peripheral lymphadenopathy (mainly cervical and axillary), and skin lesions may appear as physical examination findings.
Imaging findings: Scadding staging is performed on chest X-ray. Stage 1 is bilateral hilar lymphadenopathy only (lymphadenopathy symmetric and potato-shaped), stage 2 is hilar enlargement accompanied by lung parenchymal infiltrates, stage 3 is pulmonary infiltrates only without hilar lymphadenopathy, and stage 4 is pulmonary fibrosis, cystic change, and upper lobe retraction. HRCT (high-resolution CT) is much more sensitive and specific than chest X-ray, with centrilobular nodules, peribronchovascular nodules, interlobular thickening, ground-glass opacities, pulmonary cavities (in lung stage 4), and traction bronchiectasis as characteristic findings.
Pulmonary function tests typically show a restrictive ventilatory defect, with decreased vital capacity (FVC) and total lung capacity (TLC) and a normal FEV1/FVC ratio. When there is pulmonary fibrosis or airway granulomatous infiltration, FEV1 is decreased, and a mixed or obstructive defect may appear. A decrease in diffusing capacity for carbon monoxide (DLco) reflects a gas exchange abnormality and may change before radiologic findings, making it useful for tracking the disease. Serum angiotensin-converting enzyme (ACE) may be elevated in active sarcoidosis, but its sensitivity (60%) and specificity (75%) are insufficient, so it is not used alone as a diagnostic marker. Elevated serum calcium and increased urinary calcium are also signs of active sarcoidosis.
Initial screening for pulmonary sarcoidosis is performed mainly with chest X-ray. Bilateral hilar lymphadenopathy or pulmonary nodules are often found incidentally on chest X-rays taken during health checkups or for other purposes. In adults aged 25–50 with persistent dry cough, exertional dyspnea, unexplained fatigue, or fever, sarcoidosis should be included in the differential diagnosis and a chest X-ray performed.
If an abnormality is found on chest X-ray, chest HRCT is performed to evaluate more accurately the distribution of lesions, nodule size, presence of lung parenchymal infiltrates, and extent of lymphadenopathy. Pulmonary function tests (spirometry, DLco) are essential for assessing the degree of functional impairment. Because serum ACE has limited sensitivity, it is more useful for tracking treatment response than as a screening test. Serum calcium, 24-hour urinary calcium, and creatinine are measured to check for granuloma-induced abnormalities of calcium metabolism. Ophthalmologic examination (slit-lamp examination) is performed to exclude ocular involvement such as uveitis.
At the screening stage of sarcoidosis, tuberculosis must be differentiated. Because the tuberculosis prevalence in Korea is considerable, differentiation from tuberculosis is clinically very important. Active tuberculosis must be excluded by tuberculin skin test (PPD), interferon-gamma release assay (IGRA), sputum acid-fast bacilli examination, and, if necessary, bronchial wash culture. In addition, lymphoma, berylliosis, hypersensitivity pneumonitis, and fungal infections (histoplasmosis, coccidioidomycosis, etc.) are among the differential diagnoses.
Pulmonary sarcoidosis is confirmed by integrating histologic findings with clinical and imaging findings. The standard diagnostic criteria are: (1) compatible clinical and radiologic findings, (2) confirmation of non-caseating epithelioid granuloma on tissue biopsy, and (3) exclusion of similar diseases (particularly tuberculosis and fungal infections). In typical Löfgren syndrome or when imaging findings are very typical, a clinical diagnosis without tissue biopsy is also accepted.
As a method of obtaining tissue, bronchoscopy-based testing is recommended first. Performing endobronchial biopsy, bronchoalveolar lavage (BAL), and transbronchial lung biopsy (TBLB) together improves the diagnostic yield. A CD4/CD8 ratio of 3.5 or higher in BAL strongly supports sarcoidosis. Recently, endobronchial ultrasound (EBUS)-TBNA (transbronchial needle aspiration) has been widely used for biopsy of mediastinal and hilar lymph nodes, and with low invasiveness and high diagnostic accuracy (80–90%) it has become the standard procedure. Superficial lymph node biopsy, skin lesion biopsy, and conjunctival biopsy can also be performed at easily accessible sites. Surgical lung biopsy (thoracoscopic or open biopsy) is performed when a definitive diagnosis cannot be made by minimally invasive methods.
On histology, the granuloma consists of epithelioid macrophages, multinucleated giant cells, and peripheral lymphocytes, and the absence of central caseous necrosis is the key distinguishing finding from tuberculous granuloma. Fungi are excluded with PAS stain and Grocott silver stain, and Mycobacterium tuberculosis is excluded with Ziehl-Neelsen stain and culture. Polarized light microscopy can also be used to confirm the presence of foreign material (such as silica).
The key principle of treating pulmonary sarcoidosis is that treatment is not always necessary. Asymptomatic stage 1 and some stage 2 patients have a high spontaneous remission rate, so observation is considered first without immediate treatment. Chest X-ray and pulmonary function tests are followed up at 3–6 month intervals to monitor progression. Criteria for starting treatment are: (1) decline or worsening of lung function (FVC decrease of 10% or more), (2) worsening respiratory symptoms and reduced quality of life, (3) involvement of major organs such as the heart, nervous system, and eyes, (4) hypercalcemia, and (5) progression of radiologic findings.
First-line treatment is oral corticosteroids (glucocorticoids). The standard starting dose is prednisolone 0.5 mg/kg/day (maximum 40 mg/day) for 4–6 weeks, then gradually tapered according to symptoms and radiologic findings, with a total treatment duration generally of 1–2 years. Steroids are effective in suppressing granuloma formation and improving acute symptoms, but long-term use causes side effects such as osteoporosis, weight gain, diabetes, and hypertension. Inhaled steroids have fewer systemic side effects but limited efficacy, so they are used adjunctively only for mild pulmonary symptoms.
When the response to steroids is insufficient or tapering is needed because of side effects, second-line agents such as methotrexate (10–15 mg once weekly, oral or subcutaneous) or azathioprine (2–3 mg/kg per day) are added or substituted. Hydroxychloroquine is useful for skin and joint symptoms and hypercalcemia. As third-line therapy, biologics such as infliximab (anti-TNF-α monoclonal antibody) have proven effective and are used in refractory sarcoidosis, and adalimumab can also be used as an alternative. JAK inhibitors (ruxolitinib, upadacitinib, etc.) are under study as new treatment possibilities. In patients with end-stage pulmonary fibrosis (stage 4), lung transplantation may be the only treatment option.
The prognosis of pulmonary sarcoidosis varies greatly with stage, ethnicity, type of clinical presentation, and treatment response. Spontaneous remission rates by Scadding stage are about 80% for stage 1, 50–60% for stage 2, 30% for stage 3, and 10% for stage 4, so the higher the stage, the lower the likelihood of spontaneous remission. In about two-thirds of all sarcoidosis patients remission or stabilization is eventually achieved, but about one-third follow a chronic progressive course.
In Korean patients the proportion of stage 4 is 2.6%, markedly lower than 5–15% in the West, and the overall prognosis of Korean patients is interpreted as better than in the West. However, in long-term follow-up after diagnosis, quality of life may decline due to exacerbation and relapse, management of treatment side effects, and extrapulmonary organ involvement. Mortality is low at 9.25/1000 in all patients, but pulmonary hypertension, chronic respiratory failure, cardiac sarcoidosis (fatal arrhythmia), and neurosarcoidosis are the main causes of death. Management of chronic symptoms such as fatigue, dyspnea, pain, sleep disturbance, and depression and anxiety is important for improving prognosis.
Poor prognostic factors include: African American ethnicity, radiologic stage 4, cardiac, neurologic, or renal involvement at diagnosis, treatment started after symptoms persisting for 6 months or more, poor response to treatment, relapse, and simultaneous involvement of multiple organs. Conversely, presentation as Löfgren syndrome, radiologic stage 1, and acute onset (remission within 2 years is common) are favorable prognostic factors.
Because the cause of sarcoidosis is not fully understood, there is no complete primary prevention. However, minimizing exposure to known risk factors is recommended. For those working in environments with occupational exposure to organic dust, metal dust, silica, etc. (firefighters, agriculture, mining, metalworking), wearing appropriate respiratory protection (such as N95 masks) and providing ventilation systems are recommended. Smoking does not necessarily show a positive association with the development of sarcoidosis, but it worsens lung function impairment in patients who have already developed the disease, so smoking cessation is strongly recommended.
After diagnosis, regular follow-up testing is the key to secondary prevention (prevention of complications). Patients diagnosed with pulmonary sarcoidosis have chest X-ray, pulmonary function tests, serum ACE, and calcium measured at 3–6 month intervals to monitor disease progression. During treatment, to prevent steroid side effects (osteoporosis, glucose abnormalities, blood pressure abnormalities), calcium and vitamin D supplementation, regular bone density tests, and blood glucose and blood pressure monitoring are performed. Regular ophthalmologic examination (at least once a year) detects uveitis and glaucoma early. Early detection of cardiac involvement by electrocardiogram and echocardiography follow-up is also important. The development of pulmonary hypertension is assessed periodically by 6-minute walk distance test, electrocardiogram, and echocardiography.
Tertiary prevention (maintaining quality of life) includes pulmonary rehabilitation programs, fatigue management, and psychosocial support. Regular exercise of appropriate intensity (pulmonary rehabilitation) is effective in improving dyspnea and exercise tolerance. Influenza and pneumococcal vaccination are recommended to prevent infectious complications. Patients are guided to make active use of sarcoidosis patient support groups and rare disease support programs.